CN114364385A - 用于对抗代谢疾病的组合物及其用途 - Google Patents

用于对抗代谢疾病的组合物及其用途 Download PDF

Info

Publication number
CN114364385A
CN114364385A CN202080060415.1A CN202080060415A CN114364385A CN 114364385 A CN114364385 A CN 114364385A CN 202080060415 A CN202080060415 A CN 202080060415A CN 114364385 A CN114364385 A CN 114364385A
Authority
CN
China
Prior art keywords
therapeutic agent
pharmaceutical composition
mice
glucose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060415.1A
Other languages
English (en)
Inventor
黄仕强
马诗琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Zoology of CAS
Original Assignee
Institute of Zoology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Zoology of CAS filed Critical Institute of Zoology of CAS
Publication of CN114364385A publication Critical patent/CN114364385A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种用于抵抗代谢疾病的组合物及其用途(或方法)。药物组合物包含治疗剂A或其药学上可接受的盐；治疗剂B或其药学上可接受的盐；以及至少一种药学上可接受的赋形剂，其中，所述治疗剂A是非甾体抗炎药，所述治疗剂B是脂肪酸氧化抑制剂。该药物组合物可以有效治疗或预防肥胖、非酒精性脂肪肝、多囊卵巢综合征、2型糖尿病和胰岛素抵抗所导致的代谢综合征疾病。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080060415.1A 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途 Pending CN114364385A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/103677 2019-08-30
CN2019103677 2019-08-30
PCT/CN2020/112143 WO2021037212A1 (zh) 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途

Publications (1)

Publication Number Publication Date
CN114364385A true CN114364385A (zh) 2022-04-15

Family

ID=74683374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060415.1A Pending CN114364385A (zh) 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途

Country Status (9)

Country Link
US (1) US20220323408A1 (zh)
EP (1) EP4023225A4 (zh)
JP (1) JP2022546987A (zh)
KR (1) KR20220054351A (zh)
CN (1) CN114364385A (zh)
AU (1) AU2020339557A1 (zh)
CA (1) CA3152868A1 (zh)
IL (1) IL290927A (zh)
WO (1) WO2021037212A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163342A1 (en) * 2019-12-05 2021-06-10 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
US20110275649A1 (en) * 2010-05-05 2011-11-10 Palmetto Pharmaceuticals Llc Combination therapy for the prevention of statin induced diabetes
CN103384529A (zh) * 2010-12-21 2013-11-06 雀巢产品技术援助有限公司 适合于控制动物血糖的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5127093B1 (zh) 1970-11-11 1976-08-10
DE3574867D1 (de) 1984-04-02 1990-01-25 Cornell Res Foundation Inc Aminokarnitine.
HUT65327A (en) 1992-06-11 1994-05-02 Sandoz Ag Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
US20110275649A1 (en) * 2010-05-05 2011-11-10 Palmetto Pharmaceuticals Llc Combination therapy for the prevention of statin induced diabetes
CN103384529A (zh) * 2010-12-21 2013-11-06 雀巢产品技术援助有限公司 适合于控制动物血糖的方法和组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
OMAR M.E. ABDEL-SALAM等: "Pharmacological Investigation of Trimetazidine in Models of Infl ammation, Pain and Gastric Injury in Rodents", 《PHARMACOLOGY》 *
RIPUDAMAN S. HUNDAL等: "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
吕煜等: "曲美他嗪联合阿司匹林治疗不稳定型心绞痛82例的临床研究", 《中国伤残医学》 *
王振国: "曲美他嗪联合阿司匹林治疗冠心病 合并心力衰竭患者的临床疗效", 《山西医药杂志》 *
高远等: "2型糖尿病与炎症的研究进展", 《中华临床医师杂志( 电子版)》 *

Also Published As

Publication number Publication date
AU2020339557A1 (en) 2022-03-24
WO2021037212A9 (zh) 2022-03-24
IL290927A (en) 2022-04-01
EP4023225A1 (en) 2022-07-06
JP2022546987A (ja) 2022-11-10
KR20220054351A (ko) 2022-05-02
EP4023225A4 (en) 2023-08-30
CA3152868A1 (en) 2021-03-04
WO2021037212A1 (zh) 2021-03-04
US20220323408A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
Giri et al. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity
AU2018253580B2 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
Hammoudi et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes
Impellizzeri et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD)
Rizos et al. The current role of thiazolidinediones in diabetes management
Marketou et al. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol
ES2959111T3 (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de Nrf2
Rizos et al. Pleiotropic effects of thiazolidinediones
Hoong et al. SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases
KR20190108141A (ko) 조합 치료요법용 약학 조성물
US10617689B2 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
Lima et al. Central role of obesity in endothelial cell dysfunction and cardiovascular risk
WO2021037212A1 (zh) 用于对抗代谢疾病的组合物及其用途
Bakkar et al. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease
RU2827553C1 (ru) Композиция, используемая для борьбы с метаболическими заболеваниями, и применения композиции
EP3703670A1 (en) Compositions and methods for treating septic cardiomyopathy
Tajima et al. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes
AU2005306488A1 (en) Use of methyl pyruvate to increase cellular energy production downstream of glycolysis
Dunford The relationship between elevations in glucocorticoids and diabetes development in Rats on skeletal muscle Insulin resistance and the microvasculature
US20240261296A1 (en) Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes
CA2512618C (en) Use of r-4-trimethylammonio-3-(tetradecyl-carbamoyl)-aminobutyrate and metformin for the treatment of diabetes
US20100144873A1 (en) Treatment of myocarditis using fts
Colson Is high-intensity interval training as efficient as moderate-intensity training in reversing the adverse effects of diabetic cardiomyopathy?
Bhadania et al. PPAR-α/γ AGONISTS: A NEWER APPROACH TO DIABETIC DYSLIPIDEMIA
Zeng Anti-diabetic effects of oleanolic acid and matrine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination